Allovir Inc at JPMorgan Healthcare Conference Transcript
Thanks, everyone. Welcome to the Tuesday afternoon session of the 41st Annual JPMorgan Healthcare Conference. My name is Anupam Rama. I'm one of the senior biotech analysts here at JPMorgan. I'm joined by my colleagues, Malcolm Kuno and Priyanka Grover. Our next presenting company is AlloVir, and presenting on behalf of the company, we have CEO, Diana Brainard.
Thanks, Anupam, and thanks to everyone for being in the room today and on the line. It's really nice to be in person and looking at a group of real people. I'm -- you're real, right? I'm really happy to be providing an update on AlloVir and the excellent progress we've made over the last year and talk about where we're headed in 2023 and beyond.
As a starting point, we're a platform company developing allogeneic, off-the-shelf, virus-specific T cell therapies to address life-threatening viral diseases through either treatment or prevention in immunocompromised patients.
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
